Therefore, 2 recent, sufficiently powered, randomized, controlled trials in PSP tested the hypothesis that passive immunization using monoclonal antibodies targeting the N‐terminus of tau would be efficacious to block the spreading of tau pathology and the associated disease progression. Here, MAPT is linked to supranuclear palsy, progressive, 1.